Jacobio Jacobio Pharmaceuticals Group (北京加科思新药研发有限公司, formerly known as Jacobio (Cay) Pharmaceuticals) is a pharmaceutical company that provides therapy solutions. | Luye Pharma Luye Pharma Group (绿叶制药) is a pharmaceutical company that develops, manufactures, and sells medications. | ![]() Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients. | ||
Founding Date | Founding Date 2015 | Founding Date 2009 | Founding Date 1994 | Founding Date 1995 |
Type | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | ||||
Locations | Locations Beijing, CN HQ Beijing, CN Beijing, CN Shanghai, CN Lexington, US | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more | Locations CN HQ | Locations Seattle, US HQ Vancouver, CA Bothell, US Bothell, US |
Employees | Employees 257 | Employees 3,9671% decrease | Employees 5,150 | Employees 148% increase |
Financial | ||||
Revenue (est.) | Revenue (est.) ¥53.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ¥6.3b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods ¥593k (FY, 2025) | Cost of goods N/A | Cost of goods ¥1.3b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit ¥56.8m (FY, 2025) | Gross profit N/A | Gross profit ¥5.1b (FY, 2025) | Gross profit N/A |
Net income | Net income (¥146m) (FY, 2025) | Net income N/A | Net income ¥705.7m (FY, 2025) | Net income ($54.6m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 85.3m | Total funding raised N/A | Total funding raised $ 10m |

Kite Pharma is a company developing cancer immunotherapy products based on cell therapy.
View companyLuye Pharma Group (绿叶制药) is a pharmaceutical company that develops, manufactures, and sells medications.
View company
Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients.
View company